Modulating myosin function to treat hypertrophic cardiomyopathy

Abstract

Mutations in MYBPC3 cause increased cardiac contractility, reduced relaxation and excessive energy consumption characteristic of hypertrophic cardiomyopathy by disrupting normal myosin conformations. These abnormalities can be corrected by pharmacological targeting of myosin function.